Guest writer Shayna Goerdt shares the ups and downs of her journey with MS. Among the highs is advocating for the community, ...

Immunic Therapeutics was granted a patent in Europe that protects all dosing regimens of its MS therapy vidofludimus calcium ...

A study questioned the use of brain volume loss as a clinical trial endpoint in PPMS after finding a weak link to disability ...

Many MS genetic risk factors are shared across ancestral backgrounds, but European-focused studies may miss others, per a study.

Guest writer Caitlin Epstein was in the middle of world travels when her MS symptoms worsened, leading to a diagnosis.

Briumvi significantly outperformed Aubagio at reducing disease activity in people with highly active relapsing forms of MS, a ...

A Phase 1 trial testing TG Therapeutics' CAR T-cell therapy azer-cel in progressive forms of MS is now recruiting across ...

For Izzy Abbass, who grew up around mountains, climbing them, and overcoming hurdles with MS, is easier with good support.

As columnist Ahna Crum marveled at the feats of Olympic medalists, she decided to grab a pair of ice skates and test her own ...

When guest writer Antonio Perez turned to social media to learn about MS, he saw a need to help other young people navigate ...

A second clinical trial testing fenebrutinib for MS has met its main goal, once again beating approved Aubagio in reducing ...

Foralumab reduced microglial activity in people with nonactive SPMS, and this was linked to reductions in proinflammatory ...